Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

Official title

Clinical Study to Evaluate the Safety and Efficacy of Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 in the Treatment of Refractory cGVHD Subjects

Overview

This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell injection combined with recombinant human interleukin-2 in treating subjects with refractory cGVHD，and to preliminarily observe the efficacy of the study drugs in subjects with refractory cGVHD.

Detailed description

This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell injection combined with recombinant human interleukin-2 in treating subjects with refractory cGVHD，and to preliminarily observe the efficacy of the study drugs in subjects with refractory cGVHD.In this study, rapid titration of the first dose group and a "3+3" rule design were used for dose escalation to minimize patient exposure to ineffective doses while minimizing the occurrence of risk.Three dose groups were set up: 1×10\^6 Treg cells /kg dose group, 5.0×10\^6 Treg cells /kg dose group and 10×10\^6Treg cells /kg dose group.One infusion per dose group.

Interventions

• Biological Donor-derived Treg cell injection combined with interleukin 2
  Subjects received Treg cell infusion at day D0, and interleukin 2 was administered subcutaneously daily from 1 week before to 12 weeks after infusion.

Primary outcome measures

• To evaluate the incidence of DLT in patients with refractory cGVHD treated with donor-derived Treg cell injection combined with low dose rhIL-2 injection [Time frame: Up to day 28]
• Incidence of grade 3 and above adverse reactions [Time frame: Through study completion, an average of 2 year]

Secondary outcome measures (11)

• Evaluate the number of Treg cells in subjects' peripheral blood [Time frame: An average of 1 year]
• Analysis of the number changes of lymphocyte subsets in peripheral blood. [Time frame: Through study completion, an average of 2 year]
• Score changes in the 36-Item Short Form Health Survey (SF-36) [Time frame: Through study completion, an average of 2 year]
• Score changes in Lee Chronic Graft-versus-Host Disease Symptom Scale [Time frame: Through study completion, an average of 2 year]
• Changes in cGVHD severity [Time frame: Through study completion, an average of 2 year]
• Objective Response Rate (ORR) [Time frame: Through study completion, an average of 2 year]
• Patient-reported Outcomes [Time frame: Through study completion, an average of 2 year]
• Proportion of subjects able to reduce steroid requirement to <0.25 mg/kg/ day. [Time frame: Through study completion, an average of 2 year]
• Duration of response after administration (DOR) [Time frame: Through study completion, an average of 2 year]
• Failure-free survival after administration (FFS) [Time frame: Through study completion, an average of 2 year]
• Overall survival [Time frame: Through study completion, an average of 2 year]

Eligibility criteria

Inclusion criteria

• Subjects aged 18-70 years old, male or female;
• The subjects had received allo-HSCT, including cord blood transplantation;
• TSubjects with moderate/severe cGVHD that meets the NIH diagnostic criteria (031) for steroid dependence or resistance, meeting one of the following:

• There was no improvement in cGVHD in initial treatment patients treated with > 0.5mg/kg/ day or 1 mg/kg/ day every other day for at least 4 weeks;
• Steroid dependence: predtisone dose > 0.25 mg/kg/d or > 0.5 mg/kg/qod cGVHD relapse or progression; cGVHD recurred after two attempts to gradually reduce prednisone dose at an interval of at least 8 weeks, with prednisone dose > 0.25 mg/kg/day to be maintained.
• Prednisone dose > 0.25 mg/kg/d for more than 4 weeks; Subjects must maintain a stable prednisone dose for 4 weeks prior to the first Treg cell infusion and not increase or discontinue other immunosuppressants (including cyclosporine, tacrolimus, and sirolimus);
• The ECOG score of the subjects was 0-2;
• the expected survival of the subject is more than 3 months;
• Liver, kidney, heart and lung function meet the following requirements (except liver and kidney dysfunction caused by cGVHD) :

• Creatinine clearance (calculated by Cockcroft Gault formula) ≥60 mL/min;
• Cardiac ejection fraction greater than 50%, no clinically significant electrocardiogram changes;
• Forced expiratory volume (FEV1) in the first second of baseline lung function ≥50%, and FEV1 decline caused by cGVHD could be included;
• Total bilirubin ≤2.0ULN; ALT and AST≤3ULN, ALT and AST increases caused by cGVHD could be included in the group.
• Hematopoietic function: neutrophils >1×10\^9/L, platelets >25×10\^9/L; Supportive treatments such as platelet transfusion and other cytokines are excluded.
• The subject or the subject's guardian can understand this experiment and has signed the informed consent.
• Donor age 14-70 years old, male or female;
• The ECOG score of the donor is 0-1;
• The donor must be a hematopoietic stem cell donor who underwent allo-HSCT prior to the subject;
• Female donors must test negative for serum or urine beta-human chorionic gonadotropin (HCG) within 3 weeks of blood collection;
• The donor can establish the necessary venous access for collection, without the contraindication of white blood cell collection; If peripheral venous leukocyte collection is insufficient, be willing to insert a central catheter; (15) The donor agrees to donate and signs a consent form.

Exclusion criteria

• Subjects had a recurrence of primary malignant disease before receiving Treg treatment;
• The subjects had persistent, recurrent or delayed aGVHD;
• Continuous use of prednisone >1 mg/kg/day is required;
• The severity of the subject's cGVHD cannot be assessed by physical examination or laboratory examination;
• overlap syndrome；
• The subjects had major organ (cardio-cerebrovascular, pulmonary) dysfunction not caused by cGVHD, and had previous (within 3 months) gastrointestinal active bleeding; History of uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy, history or evidence of significant cardiovascular and cerebrovascular risk, including any of the following conditions: congestive heart failure, unstable angina pectoris, clinically significant arrhythmias (e.g., ventricular fibrillation, ventricular tachycardia, etc.); History of arterial thrombosis (such as stroke, transient ischemic attack) within the last 3 months; A history of symptomatic deep vein thrombosis, pulmonary embolism, or coronary angiogenesis, defibrillation, or any clinically relevant complication or disease within the last 6 months that could pose a risk to subject safety or interfere with study evaluation, procedure, or completion;
• The subjects are hemodialysis patients;
• The subject or donor has an active, uncontrolled bacterial, viral, or fungal infection that requires treatment；
• The subjects are pregnant or lactating women; Subjects who plan to become pregnant during the post-transfusion study, or within 1 year of completion or withdrawal from the study;
• Participants who had received IL-2 therapy or drug therapy targeting IL-2 within 4 weeks prior to enrollment；
• Received DLI treatment within 100 days before enrollment;
• Received CAR-T or similar engineered cell therapy within 100 days prior to enrollment;
• Had received new cGVHD therapies (including imatinib, BTK inhibitors, rituximab and other immunosuppressants) within 4 weeks before enrollment after transplantation;
• Have a history of microvascular diseases such as TMA, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, etc；
• Subjects with poor IL-2 treatment compliance;
• Participants who participated in other CGVHD-related clinical studies within 4 weeks prior to enrollment;
• Subjects who are known to be allergic to any component of Treg cell injection;
• Any situation that the investigator believes would compromise the safety of the subject or interfere with the study purpose, or that the investigator considers it inappropriate to participate in the study;
• Having a medical condition that affects the signing of written informed consent or the inability to follow study procedures; Unwilling or unable to comply with research requirements;
• The donor was a pregnant woman.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Shanghai General Hospital — Shanghai

Identifiers

NCT: NCT06920199 · SHSYXY-Treg-cGVHD-2024

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗